Latest Information

Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.

  • Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

    Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

    Read Article
  • Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

    Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

    LMNL announced today that its subsidiary Prometic Biotherapeutics Inc. (“PBT”) has closed on the sale of its Priority Review Voucher (“PRV”) for USD 105 million.

    Read Article
  • Liminal BioSciences Reports Second Quarter 2021 Financial Results

    Liminal BioSciences Reports Second Quarter 2021 Financial Results

    Read Article
  • Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

    Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

    Read Article

  • Press Releases

    Read More
  • Quarterly Report Q2 2021

    Quarterly Report Q2 2021

    Read PDF
  • Quarterly Report Q1 2021

    Quarterly Report Q1 2021

    Read PDF
  • Annual Report 2020

    Annual Report 2020

    Read PDF

  • Financial Reports

    Read Now
  • loading
    Loading More...